07:00 , Sep 26, 2011 |  BC Week In Review  |  Company News

Aestus Therapeutics, Astellas deal

Astellas' Prosidion Ltd. subsidiary granted Aestus exclusive, worldwide rights to develop and commercialize ATx09-002 (formerly PSN357). Aestus plans to begin a Phase II trial of the glycogen phosphorylase inhibitor in post-herpetic neuralgia (PHN)...
00:58 , Sep 20, 2011 |  BC Extra  |  Company News

Prosidion, Aestus partner for pain compound

Prosidion Ltd., a subsidiary of Astellas Pharma Inc. (Tokyo:4503), granted Aestus Therapeutics Inc. (North Brunswick, N.J.) exclusive, worldwide rights to develop and commercialize ATx09-002 (formerly PSN357). Aestus plans to begin a Phase II trial of...